AR071478A1 - Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi - Google Patents

Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi

Info

Publication number
AR071478A1
AR071478A1 ARP090101328A ARP090101328A AR071478A1 AR 071478 A1 AR071478 A1 AR 071478A1 AR P090101328 A ARP090101328 A AR P090101328A AR P090101328 A ARP090101328 A AR P090101328A AR 071478 A1 AR071478 A1 AR 071478A1
Authority
AR
Argentina
Prior art keywords
peptide
procoagulant activity
amino acid
derivative
fviii
Prior art date
Application number
ARP090101328A
Other languages
English (en)
Spanish (es)
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of AR071478A1 publication Critical patent/AR071478A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ARP090101328A 2008-04-17 2009-04-15 Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi AR071478A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US932608P 2008-04-17 2008-04-17
US11305508P 2008-11-10 2008-11-10

Publications (1)

Publication Number Publication Date
AR071478A1 true AR071478A1 (es) 2010-06-23

Family

ID=40887122

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101328A AR071478A1 (es) 2008-04-17 2009-04-15 Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi

Country Status (19)

Country Link
US (6) US8563688B2 (OSRAM)
EP (2) EP2279200B1 (OSRAM)
JP (3) JP6038452B2 (OSRAM)
KR (2) KR101606248B1 (OSRAM)
CN (2) CN105524163A (OSRAM)
AR (1) AR071478A1 (OSRAM)
AU (1) AU2009244635B2 (OSRAM)
BR (1) BRPI0911203A2 (OSRAM)
CA (1) CA2721694C (OSRAM)
DK (2) DK2279200T3 (OSRAM)
ES (2) ES2594706T3 (OSRAM)
HK (1) HK1223946A1 (OSRAM)
MX (1) MX2010011397A (OSRAM)
NZ (1) NZ588200A (OSRAM)
PL (1) PL2279200T3 (OSRAM)
PT (1) PT2279200T (OSRAM)
SG (2) SG10201608071YA (OSRAM)
TW (2) TWI573806B (OSRAM)
WO (1) WO2009137256A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071478A1 (es) * 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
CN103262532B (zh) 2010-07-19 2018-03-09 杜比实验室特许公司 用于经采样复用的图像和视频数据的增强方法
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN119192402A (zh) 2012-02-15 2024-12-27 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2014200126A1 (ko) * 2013-06-11 2014-12-18 씨제이제일제당 (주) Ｌ-이소루신을 생산하는 미생물 및 이를 이용한 ｌ-이소루신 제조방법
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
US9321812B2 (en) 2014-03-28 2016-04-26 Perle Bioscience Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
JP6484468B2 (ja) * 2014-06-03 2019-03-13 ＡｖａｎＳｔｒａｔｅ株式会社 ガラス板製造方法およびガラス板製造装置
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
JP7035033B2 (ja) 2016-09-28 2022-03-14 コーバー、インコーポレイテッド 治療用ＭＯＴＳ－ｃ関連ペプチド
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
CR20190389A (es) 2017-01-31 2019-11-26 Bioverativ Therapeutics Inc Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
JPH0725794B2 (ja) * 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
PT693924E (pt) 1993-02-22 2004-09-30 American Biosciences Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
WO1996021024A1 (en) * 1994-12-30 1996-07-11 Asgrow Seed Company Papaya ringspot virus replicase gene
US5532153A (en) * 1995-03-23 1996-07-02 New England Biolabs, Inc. Method for cloning and producing the SacI restriction endonuclease
US7279548B2 (en) * 1996-04-03 2007-10-09 Cytogen Corporation Identification and isolation of novel polypeptides having WW domains and methods of using same
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US6624289B1 (en) 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
EP1196432A2 (en) 1999-07-02 2002-04-17 Genentech, Inc. FVIIa ANTAGONISTS
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
AU2065801A (en) * 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
EP1257289A1 (en) * 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
AU2002256518B2 (en) * 2001-05-11 2007-07-19 Research Development Foundation Inhibitors of receptor activator of NF-kappaB and uses thereof
FR2830865B1 (fr) * 2001-10-17 2004-10-22 Centre Nat Rech Scient Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes
US20060204503A1 (en) * 2005-01-31 2006-09-14 Biogen Idec Ma Inc. Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors
EP1968999A2 (en) * 2005-12-07 2008-09-17 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
KR20080090489A (ko) 2006-01-04 2008-10-08 두-쿱 테크놀로지스 리미티드 살균제 조성물 및 그 사용 방법
AR071478A1 (es) * 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi

Also Published As

Publication number Publication date
TW200944226A (en) 2009-11-01
TWI573806B (zh) 2017-03-11
HK1154255A1 (zh) 2012-04-13
EP2279200B1 (en) 2016-07-13
EP3115370A1 (en) 2017-01-11
US10822376B2 (en) 2020-11-03
CA2721694C (en) 2018-11-06
US20100022445A1 (en) 2010-01-28
PT2279200T (pt) 2016-10-12
US10287319B2 (en) 2019-05-14
CN102007140A (zh) 2011-04-06
JP2014074052A (ja) 2014-04-24
KR20130112959A (ko) 2013-10-14
KR20110005873A (ko) 2011-01-19
ES2594706T3 (es) 2016-12-22
CA2721694A1 (en) 2009-11-12
JP6038452B2 (ja) 2016-12-07
PL2279200T3 (pl) 2017-08-31
WO2009137256A1 (en) 2009-11-12
SG10201809286XA (en) 2018-11-29
JP2011518179A (ja) 2011-06-23
MX2010011397A (es) 2010-11-12
HK1223946A1 (zh) 2017-08-11
ES2739676T3 (es) 2020-02-03
CN105524163A (zh) 2016-04-27
US20120077749A1 (en) 2012-03-29
US20150038676A1 (en) 2015-02-05
EP3115370B1 (en) 2019-06-26
TW201443085A (zh) 2014-11-16
TWI541020B (zh) 2016-07-11
NZ588200A (en) 2012-11-30
JP2017019797A (ja) 2017-01-26
JP5977223B2 (ja) 2016-08-24
KR101606248B1 (ko) 2016-03-24
AU2009244635B2 (en) 2012-04-19
US9598464B2 (en) 2017-03-21
AU2009244635A1 (en) 2009-11-12
US8563688B2 (en) 2013-10-22
BRPI0911203A2 (pt) 2016-07-05
DK2279200T3 (en) 2016-08-22
US20170174724A1 (en) 2017-06-22
US8822638B2 (en) 2014-09-02
US9206234B2 (en) 2015-12-08
US20190225648A1 (en) 2019-07-25
DK3115370T3 (da) 2019-07-29
SG10201608071YA (en) 2016-11-29
KR101434712B1 (ko) 2014-10-01
US20160060295A1 (en) 2016-03-03
EP2279200A1 (en) 2011-02-02
CN102007140B (zh) 2016-02-24

Similar Documents

Publication Publication Date Title
AR071478A1 (es) Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi
GT200800063A (es) Compuestos para la inhibicion de enzimas
AR079197A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
AR087070A1 (es) Proteinas de fusion liberadoras de relaxina y usos de las mismas
AR069110A1 (es) Analogos del glucagon que tienen actividad de antagonista del glucagon
MX2013007716A (es) Sistemas de expresion.
CO6660439A2 (es) Eliminación de serina proteasa por tratamiento con dióxido de silicona finamente dividido
CO6351811A2 (es) La proteina de tuberculosis rv2386c, composiciones y usos de la misma
CL2008001171A1 (es) Composicion farmaceutica que comprende fibrinogeno, trombina y un compuesto que contiene estroncio; y su uso en el tratamiento de un hueso enfermo, dañado, deficiente o defectuoso.
RU2014143639A (ru) Регулируемые протеазой антитела
EA200970374A1 (ru) Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом
AR064720A1 (es) Microvesiculas derivadas de levadura recombinante con actividades hemostaticas y usos de las mismas
CL2017002233A1 (es) Un factor de coagulación (fvii o fviia) modificado con tres péptidos carboxi terminal de gonadotropina coriónica unidos al carboxi terminal de fvii o fviia; polinucleótido que lo codifica; composición farmacéutica que lo comprende; uso de fvii o fviia modificado para el tratamiento de coagulación de la sangre o un trastorno de coagulación; método para extender la vía media biológica de un factor de coagulación; método para producir dicho fvii o fviia.
BR112022022942A2 (pt) Réplicon de rna que codifica uma proteína spike de coronavírus estabilizada
BRPI0607326B8 (pt) composição de vacina, uso da referida composição e kit em partes
CO6260151A2 (es) Peptido de cdh3 y agente medicinal que comprende al mismo
MX2014010501A (es) Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act).
AR078445A1 (es) Agonistas del peptido natriuretico tipo b (npr -b)
CY1114618T1 (el) Βιολογικα δραστικα πεπτιδια που περιεχουν καρβοξυτελικη αργινινη
EA201691358A1 (ru) Стабильные композиции эпоксикетонов пептидов
DK1987063T3 (da) Peptider og peptidderivater, fremstilling deraf samt deres anvendelse til fremstilling af en terapeutisk og/eller præventivt aktiv farmaceutisk sammensætning
EA201500061A1 (ru) Фармацевтическая композиция для терапии легочной формы высотной болезни, вызванной кислородным голоданием и пониженным атмосферным давлением
ES2506168T3 (es) Polipéptido que tiene actividad antibacteriana y actividad que induce la angiogénesis y fármacos que contienen dicho polipéptido que curan heridas
FR2841904B1 (fr) Analogues de facteurs x clivables par la thrombine

Legal Events

Date Code Title Description
FG Grant, registration